D-0351-2022 Class II Terminated

Recalled by Perrigo Company PLC — Allegan, MI

FDA drug recall D-0351-2022 was initiated by Perrigo Company PLC on Jul 27, 2021 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications; Out of specification result obtained for impurity A during stability testing. The recall status is terminated (terminated Nov 8, 2022). Affected quantity: 7,272 containers.

Recall details

Product Type
Drugs
Report Date
Jan 12, 2022
Initiation Date
Jul 27, 2021
Termination Date
Nov 8, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
7,272 containers

Product description

up&up allergy relief, Fexofenadine Hydrochloride tablets, 24HR, 180mg/antihistamine, packaged as a) 15 count bottle, NDC 11673-571-22 UPC 3 70030 62303 7; b) 30 count bottle, NDC 11673-571-39 UPC 3 70030 62301 3; Distributed by Target Corp., Mpls., MN 55403, Made in the Czech Republic,

Reason for recall

Failed Impurities/Degradation Specifications; Out of specification result obtained for impurity A during stability testing.

Distribution pattern

Nationwide in the USA

Code information

Lot a) 1AE2334, Exp 02/28/2022; b) 1BR0462, Exp 10/31/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0351-2022
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0351-2022. Report a data issue: hello@regdatalab.com.